$AMRX

Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.

Amneal Pharmaceuticals (AMRX) rose 7% to $21.17 after FDA approval for a generic Lanreotide injection. BlossomHill Therapeutics (BLSM) climbed 6% to $27.99 following positive Phase 1/2 study results. Neogen (NEOG) increased 2% to $13.34 after reporting Q4 revenue of $225M. NeoGenomics (NEO) hit a 52-week high of $20.05 after announcing Medicare and Medicaid coverage for its RaDaR ST test.

Amneal Pharmaceuticals (AMRX) stock surged 12.5% after the FDA approved its generic lanreotide injection for immediate launch. The product targets a market where the reference drug generated $983M in annual U.S. sales. Amneal's shares have seen limited volatility, with this move being rare. The company's stock is up 62% year-to-date, reaching a new 52-week high at $20.51.

FDA approved Amneal Pharmaceuticals’ lanreotide injection (120 mg/0.5 mL single-dose prefilled syringe), referencing Ipsen’s Somatuline Depot and carrying Competitive Generic Therapy designation. Amneal says it launched immediately. Somatuline Depot had $983M in US sales (12 months ended July 2026).

Amneal Pharmaceuticals (AMRX) shares rose 2% after-hours following FDA approval of its lanreotide injection, a generic version of Ipsen's Somatuline Depot. The drug, with $983M in U.S. sales (IQVIA), treats growth hormone disorders and tumors. Amneal plans immediate launch, aiming to leverage the product for growth. AMRX stock is up 48% YTD.

Amneal Pharmaceuticals (AMRX) received FDA approval and launched its lanreotide injection, a generic version of SOMATULINE® Depot, with U.S. sales of $983M for the 12 months ended July 2026. The product, indicated for acromegaly, GEP-NETs, and carcinoid syndrome, has CGT designation and is expected to drive growth for Amneal's Affordable Medicines business.

Analysts updated price targets for several companies. Guggenheim cut LYFT's target to $16, Barclays raised AMRX's to $20, Baird lowered JBHT's to $290, Canaccord boosted CRM's to $300, Keybanc increased APPF's to $280, Canaccord cut FLNC's to $15, Bernstein raised CRWD's to $132, Cantor Fitzgerald lowered ON's to $90, Morgan Stanley increased CIEN's to $450, and BTIG raised OKTA's to $219.

Amneal Pharmaceuticals (AMRX) shares rose 8.6% to $18.08 on high volume, reversing a 8.5% four-week loss. The gain followed the completion of its acquisition of Kashiv BioSciences, which the company called a long-term growth driver. Amneal expects Q2 earnings of $0.23 per share, up 35.3% YoY, and revenue of $817.01 million, up 4.1% YoY, but EPS estimates were revised 23.1% lower over 30 days. The stock has a Zacks Rank of #3 (Hold).

Kevin Buchi, a board member of Amneal Pharmaceuticals (AMRX), exercised stock options for 20,445 shares, realizing $54,179. AMRX shares are down 1.39%, trading at $17.1. The company reported 9.89% revenue growth over 3 months but faces profitability and debt challenges, with a P/E ratio of 35.89 and a debt-to-equity ratio of 84.54.

Amneal Pharmaceuticals (AMRX) completed its acquisition of Kashiv BioSciences, aiming to become a top biosimilars player. Q2 2026 revenue rose 10% to $796M, net income doubled to $58M. Amneal raised its full-year revenue outlook to $3.10B-$3.20B. The deal adds $350M in debt and increases capex guidance to $150M. Hedge fund ownership fell, but short interest remains low.